INTERNATIONAL LUNCH SYMPOSIUM

Submassive Pulmonary Embolism
High Incidence, High Morbidity, High Mortality
Is There a New Treatment?

Friday, November 18, 2011
12:00 p.m. - 1:15 p.m.
Madison Suite, Second Floor

- Sponsored by EKOS Corporation -

Submassive PE:  underrecognized and undertreated		Victor Tapson, MD
Literature review of PE incidence, morbidity & mortality		Professor of Medicine Duke University Medical Center Durham, NC
Reversal of right heart dysfunction within 48 hours of treatment		Tod Engelhardt, MD
30 patient study Procedural video		Chair, Cardiovascular & Thoracic Surgery Division East Jefferson General Hospital Metairie, LA
ULTIMA randomized controlled clinical trial		Iris Baumgartner, MD
Trial Overview Single center experience & procedural video		Professor of Internal Medicine University Hospital Bern, Switzerland
Aggressive treatment of submassive pulmonary embolism		Peter Lin, MD
Single center experience		Professor of Surgery Baylor College of Medicine Houston, TX
Panel Discussion

CE Marked Indications:  The EkoSonic® Endovascular Device is intended for controlled and selective infusion of physician-specified fluids, including thrombolytics, into the peripheral vasculature.  The EkoSonic® Endovascular Device is intended for the treatmeent of pulmonary embolism patients with a ≥ 50% clot burden in one or both main pulmonary arteries or lobar pulmonary arteries, and evidence of right heart dysfunction based on right heart pressure (mean pulmonary artery pressure  ≥ 25 mmHg) or echocardiogram evaluation.

US FDA Cleared Indications:  The EkoSonic® Endovascular Device is intended for controlled and selective infusion of physician-specified fluids, including thrombolytics, into the peripheral vasculature.  The EkoSonic® System is cleared for the infusion of solutions into the pulmonary arteries.

Information presented will include treatment not yet cleared by FDA.